_id

683a165cc782e11e38d1b390

id

10557

title

Mayo Alliance Prognostic System (MAPS) Score

full_title

Mayo Alliance Prognostic System (MAPS) Score

short_title

MAPS Score

med_description

Evaluates prognosis of systemic mastocytosis.

short_description

Systemic mastocytosis prognosis.

slug

mayo-alliance-prognostic-system-maps-score

description

The Mayo Alliance Prognostic System (MAPS) Score evaluates prognosis of systemic mastocytosis.

keywords

Mayo Alliance Prognostic System (MAPS) Score, MAPS Score, Mast cell activation disorders, MCAD, bone marrow, mast cell, MC, mast cell activation, systemic mastocytosis, SM, MC clonality, serum baseline tryptase, sBt, indolent systemic mastocytosis, ISM, clonal MCAD, c-MCAD, nonclonal MCAD, nc-MCAD, clonal sMCAD, c-sMCAD, nonclonal sMCAD, nc-sMCAD, cutaneous mastocytosis, CM, MC sarcoma, MCS, smoldering SM, SSM, indolent SM, ISM, aggressive SM, ASM, SM-AHN, MC leukemia, MCL, MC activation syndrome, MCAS

complaint

[ "Abdominal Pain", "Diarrhea", "Dizziness", "Lymphadenopathy", "Myalgias", "Nausea", "Preventive Care/Screening", "Rash", "Shortness of Breath", "Syncope", "Vomiting", "Wheezing", "Bone Pain" ]

formula

The MAPS Score is calculated by adding the selected points for each variable: *IncludesASXL1, RUNX1,andNRASmutations

evidence

measurements

[]

information

Interpretation:

refrences

{ "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Original/Primary Reference": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/30413432/", "text": "Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances. 2018;2(21):2964-2972." } ], "Other References": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/30833549/", "text": "Pardanani A, Lasho TL, Reichard KK, Hanson CA, Tefferi A. World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer J. 2019;9(3):29." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/37309222/", "text": "Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American J Hematol. 2023;98(7):1097-1116." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/38067330/", "text": "Li JY, Ryder CB, Zhang H, et al. Review and updates on systemic mastocytosis and related entities. Cancers. 2023;15(23):5626." } ], "Outcomes": [], "Validation": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/30741929/", "text": "Mannelli F, Gesullo F, Rotunno G, et al. Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer Journal. 2019;9(2):18." } ], "Validations": [] }

pearls

• Requires initial stratification of SM based on the WHO classification system.
• This hybrid clinical-molecular version of the tool is applicable to indolent/smoldering SM (ISM/SSM) and advanced SM subtypes.
• A variant of this tool is available that only incorporates clinical data.
• Note: “Advanced SM” encompasses SM variants that extend beyond indolent or smoldering forms.

usecase

Designed to be used at the bedside to risk stratify adult patients with systemic mastocytosis (SM).

reasons

Provides prognosis estimates in SM using clinical and molecular information.

next_advice

• A higher score is associated with a poorer prognosis.
• Results should be integrated into a comprehensive evaluation to inform management decisions, such as opting for more aggressive treatment strategies when necessary.

next_actions

next_management

diseases

[ "Asthma", "Autoimmune Disorders", "Osteoporosis", "Systemic Mastocytosis", "Anaphylaxis" ]

input_schema

[ { "conditionality": null, "default": 0, "label_en": "<p><abbr title=\"Systemic mastocytosis\">SM</abbr> type</p>", "mdcalc_info_concept": null, "name": "q1", "option_fhir_rules": null, "optional": false, "options": [ { "label": "Indolent SM/smoldering SM", "value": 0 }, { "label": "Advanced SM", "value": 2 } ], "show_points": true, "tips_en": "", "type": "radio" }, { "conditionality": null, "default": 0, "label_en": "<p>Age, years</p>", "md_calc_info_concept": null, "name": "q2", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≤60", "value": 0 }, { "label": ">60", "value": 1 } ], "show_points": true, "tips_en": "", "type": "toggle" }, { "conditionality": null, "default": 0, "label_en": "<p>Platelets</p>", "mdcalc_info_concept": null, "name": "q3", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≥150×10⁹/L", "value": 0 }, { "label": "<150×10⁹/L", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }, { "conditionality": null, "default": 0, "label_en": "<p>Serum ALP</p>", "mdcalc_info_concept": null, "name": "q4", "option_fhir_rules": null, "optional": false, "options": [ { "label": "Within normal range", "value": 0 }, { "label": "Above normal range", "value": 1 } ], "show_points": true, "tips_en": "", "type": "radio" }, { "conditionality": null, "default": 0, "label_en": "<p>Adverse mutations</p>", "md_calc_info_concept": null, "name": "q5", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": true, "tips_en": "(i.e., <i>ASXL1</i>, <i>RUNX1</i>, <i>NRAS</i>)", "type": "toggle" } ]

instructions

published

2024-08-08T15:43:03.226Z

purpose

[ "Prognosis" ]

search_terms

[ "Mayo Alliance Prognostic System (MAPS) Score", "MAPS Score", "Mast cell activation disorders", "MCAD", "bone marrow", "mast cell", "MC", "mast cell activation", "systemic mastocytosis", "SM", "MC clonality", "serum baseline tryptase", "sBt", "indolent systemic mastocytosis", "ISM", "clonal MCAD", "c-MCAD", "nonclonal MCAD", "nc-MCAD", "clonal sMCAD", "c-sMCAD", "nonclonal sMCAD", "nc-sMCAD", "cutaneous mastocytosis", "CM", "MC sarcoma", "MCS", "smoldering SM", "SSM", "indolent SM", "ISM", "aggressive SM", "ASM", "SM-AHN", "MC leukemia", "MCL", "MC activation syndrome", "MCAS" ]

seo

{ "keywords_en": "Mayo Alliance Prognostic System (MAPS) Score, MAPS Score, Mast cell activation disorders, MCAD, bone marrow, mast cell, MC, mast cell activation, systemic mastocytosis, SM, MC clonality, serum baseline tryptase, sBt, indolent systemic mastocytosis, ISM, clonal MCAD, c-MCAD, nonclonal MCAD, nc-MCAD, clonal sMCAD, c-sMCAD, nonclonal sMCAD, nc-sMCAD, cutaneous mastocytosis, CM, MC sarcoma, MCS, smoldering SM, SSM, indolent SM, ISM, aggressive SM, ASM, SM-AHN, MC leukemia, MCL, MC activation syndrome, MCAS", "meta_description_en": "The Mayo Alliance Prognostic System (MAPS) Score evaluates prognosis of systemic mastocytosis." }

specialty

[ "Allergy and Immunology", "Dermatology", "Family Practice", "Internal Medicine", "Primary Care" ]

departments

[ "Allergic", "Dermatologic", "Immunologic" ]

tags

[]

version_number

1

versions

[]

related

[ { "calcId": 10555, "short_title_en": "WHO Diagnostic Criteria for Systemic Mastocytosis", "slug": "world-health-organization-who-diagnostic-criteria-systemic-mastocytosis" }, { "calcId": 10556, "short_title_en": "ICC Diagnostic Criteria for Systemic Mastocytosis", "slug": "international-consensus-classification-icc-diagnostic-criteria-systemic-mastocytosis" }, { "calcId": 10554, "short_title_en": "REMA Score", "slug": "spanish-network-mastocytosis-rema-score" } ]

ismed

false

section

[ "whenToUseViewed", "pearlsPitfallsViewed", "whyUseViewed", "nextStepsViewed", "evidenceViewed" ]

cleaned_departments

[ "immunology", "dermatology", "immunology" ]

cleaned_use

[ "Designed to be used at the bedside to risk stratify adult patients with systemic mastocytosis (SM)." ]

pub

false